Skip to main content
Erschienen in: Acta Diabetologica 1/2012

01.02.2012 | Original Article

Association between serum C-peptide levels and chronic microvascular complications in Korean type 2 diabetic patients

verfasst von: Bo-Yeon Kim, Chan-Hee Jung, Ji-Oh Mok, Sung-Koo Kang, Chul-Hee Kim

Erschienen in: Acta Diabetologica | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

This study evaluated the association between serum C-peptide levels and chronic vascular complications in Korean patients with type 2 diabetes. Data for 1,410 patients with type 2 diabetes were evaluated cross-sectionally. Fasting and postprandial 2-hour serum C-peptide levels were analyzed with respect to diabetic micro- and macrovascular complications. In the group of patients with lower fasting serum C-peptide quartile, the prevalences of diabetic retinopathy and neuropathy were significantly higher (P = 0.035, P < 0.001, respectively). In the group of patients with lower delta C-peptide (postprandial − fasting C-peptide) quartile, the prevalences of diabetic retinopathy, nephropathy, and neuropathy were significantly higher (P < 0.001 for all). Low delta C-peptide quartile was also associated with increased severity of retinopathy and nephropathy. The age- and sex-adjusted odds ratios (ORs) for retinopathy, neuropathy, and nephropathy in the lowest versus the highest delta C-peptide quartile were 6.45 (95% confidence interval 3.41–12.22), 3.01 (2.16–4.19), and 2.65 (1.71–4.12), respectively. After further adjustment for the duration of diabetes, type of antidiabetic therapy, mean hemoglobin A1c, body mass index, and blood pressure, the ORs were reduced to 2.83 (1.32–6.08), 1.68 (1.12–2.53), and 1.61 (1.05–2.47), respectively, but remained significant. No significant difference was observed in the prevalence of macrovascular complications with respect to fasting or delta C-peptide quartiles. These results suggest that low C-peptide level is associated with diabetic microvascular, but not macrovascular complications in patients with type 2 diabetes mellitus.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Prando R, Odetti P, Melga P, Giusti R, Ciuchi E, Cheli V (1996) Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Postprandial plasma C-peptide level is an indication of insulin dependency. Diabetes Metab 22:185–191PubMed Prando R, Odetti P, Melga P, Giusti R, Ciuchi E, Cheli V (1996) Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Postprandial plasma C-peptide level is an indication of insulin dependency. Diabetes Metab 22:185–191PubMed
2.
Zurück zum Zitat Haupt E, Haupt A, Herrmann R, Benecke-Timp A, Vogel H, Walter C (1999) The KID study V: the natural history of type 2 diabetes in younger patients still practising a profession. Heterogeneity of basal and reactive C-peptide levels in relation to BMI, duration of disease, age and HbA1. Exp Clin Endocrinol Diabetes 107:236–243PubMedCrossRef Haupt E, Haupt A, Herrmann R, Benecke-Timp A, Vogel H, Walter C (1999) The KID study V: the natural history of type 2 diabetes in younger patients still practising a profession. Heterogeneity of basal and reactive C-peptide levels in relation to BMI, duration of disease, age and HbA1. Exp Clin Endocrinol Diabetes 107:236–243PubMedCrossRef
3.
Zurück zum Zitat Johansson J, Ekberg K, Shafqat J et al (2002) Molecular effects of proinsulin C-peptide. Biochem Biophys Res Commun 295:1035–1040PubMedCrossRef Johansson J, Ekberg K, Shafqat J et al (2002) Molecular effects of proinsulin C-peptide. Biochem Biophys Res Commun 295:1035–1040PubMedCrossRef
4.
Zurück zum Zitat Hills CE, Brunskill NJ, Squires PE (2010) C-peptide as a therapeutic tool in diabetic nephropathy. Am J Nephrol 31:389–397PubMedCrossRef Hills CE, Brunskill NJ, Squires PE (2010) C-peptide as a therapeutic tool in diabetic nephropathy. Am J Nephrol 31:389–397PubMedCrossRef
5.
Zurück zum Zitat Mughal RS, Scragg JL, Lister P et al (2010) Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein. Diabetologia 53:1761–1771PubMedCrossRef Mughal RS, Scragg JL, Lister P et al (2010) Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein. Diabetologia 53:1761–1771PubMedCrossRef
6.
Zurück zum Zitat Suzuki K, Watanabe K, Motegi T, Kajinuma H (1989) High prevalence of proliferative retinopathy in diabetic patients with low pancreatic B-cell capacity. Diabetes Res Clin Pract 6:45–52PubMedCrossRef Suzuki K, Watanabe K, Motegi T, Kajinuma H (1989) High prevalence of proliferative retinopathy in diabetic patients with low pancreatic B-cell capacity. Diabetes Res Clin Pract 6:45–52PubMedCrossRef
7.
Zurück zum Zitat Steffes MW, Sibley S, Jackson M, Thomas W (2003) Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 26:832–836PubMedCrossRef Steffes MW, Sibley S, Jackson M, Thomas W (2003) Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 26:832–836PubMedCrossRef
8.
Zurück zum Zitat Panero F, Novelli G, Zucco C et al (2009) Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 32:301–305PubMedCrossRef Panero F, Novelli G, Zucco C et al (2009) Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 32:301–305PubMedCrossRef
9.
Zurück zum Zitat Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G (2000) Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. Acta Diabetol 37:125–129PubMedCrossRef Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G (2000) Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. Acta Diabetol 37:125–129PubMedCrossRef
10.
Zurück zum Zitat Sari R, Balci MK (2005) Relationship between C peptide and chronic complications in type-2 diabetes mellitus. J Natl Med Assoc 97:1113–1118PubMed Sari R, Balci MK (2005) Relationship between C peptide and chronic complications in type-2 diabetes mellitus. J Natl Med Assoc 97:1113–1118PubMed
11.
Zurück zum Zitat Inukai T, Matsutomo R, Tayama K, Aso Y, Takemura Y (1999) Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type-2 diabetes mellitus. Exp Clin Endocrinol Diabetes 107:40–45PubMedCrossRef Inukai T, Matsutomo R, Tayama K, Aso Y, Takemura Y (1999) Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type-2 diabetes mellitus. Exp Clin Endocrinol Diabetes 107:40–45PubMedCrossRef
12.
Zurück zum Zitat Ahn HJ, Han KA, Kwon HR et al (2010) Small rice bowl-based meal plan versus food exchange-based meal plan for weight, glucose and lipid control in obese type 2 diabetic patients. Korean Diabetes J 34:86–94PubMedCrossRef Ahn HJ, Han KA, Kwon HR et al (2010) Small rice bowl-based meal plan versus food exchange-based meal plan for weight, glucose and lipid control in obese type 2 diabetic patients. Korean Diabetes J 34:86–94PubMedCrossRef
13.
Zurück zum Zitat Wilkinson CP, Ferris FL 3rd, Klein RE et al (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677–1682PubMedCrossRef Wilkinson CP, Ferris FL 3rd, Klein RE et al (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677–1682PubMedCrossRef
14.
Zurück zum Zitat Casellini CM, Barlow PM, Rice AL et al (2007) A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care 30:896–902PubMedCrossRef Casellini CM, Barlow PM, Rice AL et al (2007) A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care 30:896–902PubMedCrossRef
15.
Zurück zum Zitat Pitei DL, Watkins PJ, Stevens MJ, Edmonds ME (1994) The value of the Neurometer in assessing diabetic neuropathy by measurement of the current perception threshold. Diabet Med 11:872–876PubMedCrossRef Pitei DL, Watkins PJ, Stevens MJ, Edmonds ME (1994) The value of the Neurometer in assessing diabetic neuropathy by measurement of the current perception threshold. Diabet Med 11:872–876PubMedCrossRef
16.
Zurück zum Zitat De Bacquer D, De Backer G, Kornitzer M, Blackburn H (1998) Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease death in men and women. Heart 80:570–577PubMed De Bacquer D, De Backer G, Kornitzer M, Blackburn H (1998) Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease death in men and women. Heart 80:570–577PubMed
17.
Zurück zum Zitat De Bacquer D, De Backer G, Kornitzer M (2000) Prevalences of ECG findings in large population based samples of men and women. Heart 84:625–633PubMedCrossRef De Bacquer D, De Backer G, Kornitzer M (2000) Prevalences of ECG findings in large population based samples of men and women. Heart 84:625–633PubMedCrossRef
18.
Zurück zum Zitat Samnegard B, Jacobson SH, Jaremko G, Johansson BL, Sjoquist M (2001) Effects of C-peptide on glomerular and renal size and renal function in diabetic rats. Kidney Int 60:1258–1265PubMedCrossRef Samnegard B, Jacobson SH, Jaremko G, Johansson BL, Sjoquist M (2001) Effects of C-peptide on glomerular and renal size and renal function in diabetic rats. Kidney Int 60:1258–1265PubMedCrossRef
19.
Zurück zum Zitat Djemli-Shipkolye A, Gallice P, Coste T et al (2000) The effects ex vivo and in vitro of insulin and C-peptide on Na/K adenosine triphosphatase activity in red blood cell membranes of type 1 diabetic patients. Metabolism 49:868–872PubMedCrossRef Djemli-Shipkolye A, Gallice P, Coste T et al (2000) The effects ex vivo and in vitro of insulin and C-peptide on Na/K adenosine triphosphatase activity in red blood cell membranes of type 1 diabetic patients. Metabolism 49:868–872PubMedCrossRef
20.
Zurück zum Zitat Ekberg K, Brismar T, Johansson BL, Jonsson B, Lindstrom P, Wahren J (2003) Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes 52:536–541PubMedCrossRef Ekberg K, Brismar T, Johansson BL, Jonsson B, Lindstrom P, Wahren J (2003) Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes 52:536–541PubMedCrossRef
21.
Zurück zum Zitat Wahren J, Ekberg K, Johansson J et al (2000) Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab 278:E759–E768PubMed Wahren J, Ekberg K, Johansson J et al (2000) Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab 278:E759–E768PubMed
22.
Zurück zum Zitat Forst T, De La Tour DD, Kunt T et al (2000) Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+, K+-ATPase activity in diabetes mellitus type I. Clin Sci (Lond) 98:283–290CrossRef Forst T, De La Tour DD, Kunt T et al (2000) Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+, K+-ATPase activity in diabetes mellitus type I. Clin Sci (Lond) 98:283–290CrossRef
23.
Zurück zum Zitat Nordquist L, Shimada K, Ishii T, Furuya DT, Kamikawa A, Kimura K (2010) Proinsulin C-peptide prevents type-1 diabetes-induced decrease of renal Na+, K+-ATPase alpha1-subunit in rats. Diabetes Metab Res Rev 26:193–199PubMedCrossRef Nordquist L, Shimada K, Ishii T, Furuya DT, Kamikawa A, Kimura K (2010) Proinsulin C-peptide prevents type-1 diabetes-induced decrease of renal Na+, K+-ATPase alpha1-subunit in rats. Diabetes Metab Res Rev 26:193–199PubMedCrossRef
24.
Zurück zum Zitat Lee SK, Lee JO, Kim JH et al (2010) C-peptide stimulates nitrites generation via the calcium-JAK2/STAT1 pathway in murine macrophage Raw264.7 cells. Life Sci 86:863–868PubMedCrossRef Lee SK, Lee JO, Kim JH et al (2010) C-peptide stimulates nitrites generation via the calcium-JAK2/STAT1 pathway in murine macrophage Raw264.7 cells. Life Sci 86:863–868PubMedCrossRef
25.
Zurück zum Zitat Johansson BL, Kernell A, Sjoberg S, Wahren J (1993) Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab 77:976–981PubMedCrossRef Johansson BL, Kernell A, Sjoberg S, Wahren J (1993) Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab 77:976–981PubMedCrossRef
26.
Zurück zum Zitat Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J (2000) Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabet Med 17:181–189PubMedCrossRef Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J (2000) Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabet Med 17:181–189PubMedCrossRef
27.
Zurück zum Zitat Johansson BL, Wahren J, Pernow J (2003) C-peptide increases forearm blood flow in patients with type 1 diabetes via a nitric oxide-dependent mechanism. Am J Physiol Endocrinol Metab 285:E864–E870PubMed Johansson BL, Wahren J, Pernow J (2003) C-peptide increases forearm blood flow in patients with type 1 diabetes via a nitric oxide-dependent mechanism. Am J Physiol Endocrinol Metab 285:E864–E870PubMed
28.
Zurück zum Zitat Walcher D, Babiak C, Poletek P et al (2006) C-Peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2. Circ Res 99:1181–1187PubMedCrossRef Walcher D, Babiak C, Poletek P et al (2006) C-Peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2. Circ Res 99:1181–1187PubMedCrossRef
29.
Zurück zum Zitat Ido Y, Vindigni A, Chang K et al (1997) Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 277:563–566PubMedCrossRef Ido Y, Vindigni A, Chang K et al (1997) Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 277:563–566PubMedCrossRef
30.
Zurück zum Zitat Cotter MA, Ekberg K, Wahren J, Cameron NE (2003) Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 52:1812–1817PubMedCrossRef Cotter MA, Ekberg K, Wahren J, Cameron NE (2003) Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 52:1812–1817PubMedCrossRef
31.
Zurück zum Zitat Hovorka R, Chassin L, Luzio SD, Playle R, Owens DR (1998) Pancreatic beta-cell responsiveness during meal tolerance test: model assessment in normal subjects and subjects with newly diagnosed noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 83:744–750PubMedCrossRef Hovorka R, Chassin L, Luzio SD, Playle R, Owens DR (1998) Pancreatic beta-cell responsiveness during meal tolerance test: model assessment in normal subjects and subjects with newly diagnosed noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 83:744–750PubMedCrossRef
32.
Zurück zum Zitat Pasquali R, Buratti P, Biso P et al (1987) Estimation of B-cell function by the urinary excretion rate of C-peptide in diabetic patients: comparison with C-peptide response to glucagon and to a mixed meal. Diabete Metab 13:44–51PubMed Pasquali R, Buratti P, Biso P et al (1987) Estimation of B-cell function by the urinary excretion rate of C-peptide in diabetic patients: comparison with C-peptide response to glucagon and to a mixed meal. Diabete Metab 13:44–51PubMed
33.
Zurück zum Zitat Kim RS, Son YJ, Yang IM et al (1985) Postprandial 2-hr serum C-peptide concentration as a guide for insulin treatment in patients with NIDDM. Korean J Intern Med 28:779–786 Kim RS, Son YJ, Yang IM et al (1985) Postprandial 2-hr serum C-peptide concentration as a guide for insulin treatment in patients with NIDDM. Korean J Intern Med 28:779–786
Metadaten
Titel
Association between serum C-peptide levels and chronic microvascular complications in Korean type 2 diabetic patients
verfasst von
Bo-Yeon Kim
Chan-Hee Jung
Ji-Oh Mok
Sung-Koo Kang
Chul-Hee Kim
Publikationsdatum
01.02.2012
Verlag
Springer Milan
Erschienen in
Acta Diabetologica / Ausgabe 1/2012
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-010-0249-6

Weitere Artikel der Ausgabe 1/2012

Acta Diabetologica 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.